Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Deep-pocketed investors have adopted a bullish approach towards Merck & Co MRK, and it's something market players shouldn't ...

Merck (MRK) ended the recent trading session at $117.17, demonstrating a -0.05% swing from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily loss of 0.19%.

Merck ( MRK 0.53%) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

STAT's podcast The Readout Loud discusses Summit's cancer immunotherapy, the company's co-CEO, Moderna's spending cuts and ...

Recursion Pharmaceuticals has an exciting approach to developing therapies. The company recently reported positive phase 2 ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

Merck KGaA (0O14 – Research Report) received a Buy rating and a €205.00 price target from Goldman Sachs analyst James Quigley today. The ...

In the world of pharmaceuticals, companies aim to operate under GMP guidelines — a set of production and manufacturing ...